TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30321746

Group type: EXPERIMENTAL
Intervention: Positive Self Reference Training (PSRT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control training (NTC)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both groups (PSRT and NTC)
Number of subjects: 87
Study: 26446117

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 25458646

Group type: EXPERIMENTAL
Intervention: Transradial intervention (TRI)
Number of subjects: 14000

Group type: EXPERIMENTAL
Intervention: Bivalirudin infusion
Number of subjects: 14000

Group type: COMPARATOR
Intervention: Transfemoral coronary intervention
Number of subjects: 14000

Group type: COMPARATOR
Intervention: Unfractionated heparin plus glycoprotein IIb/IIIa inhibitors
Number of subjects: 14000
Study: 22835702

Group type: EXPERIMENTAL
Intervention: Synbiotic food supplement (containing fructo‐oligosaccharides and probiotic strains)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Synbiotic food supplement
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Synbiotic food supplementation
Number of subjects: 111
Study: 21055143

Group type: EXPERIMENTAL
Intervention: Thymopetide (2 mg/day i.m. for 75 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Regular therapy
Number of subjects: 48
Study: 18948651

Group type: EXPERIMENTAL
Intervention: Shantetra
Number of subjects: 151

Group type: COMPARATOR
Intervention: Tritanrix HB
Number of subjects: 151
Study: 15993253

Group type: EXPERIMENTAL
Intervention: SSRI antidepressants (specific SSRIs not detailed)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Discontinued SSRI treatment
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Patients who switched SSRIs
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Baseline patient skepticism about taking an antidepressant
Number of subjects: 573
Study: 12669133

Group type: EXPERIMENTAL
Intervention: Low intensity anticoagulation (target INR = 2)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Moderate intensity anticoagulation (target INR = 3)
Number of subjects: 103
Study: 10801969

Group type: EXPERIMENTAL
Intervention: High dose zinc supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose antioxidants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8719121

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BL) at 3000 lux for 6 days after PSD
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dim light therapy (DL) at 100 lux for 6 days after PSD
Number of subjects: 20
Study: 1595849

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg pretreatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6486083

Group type: COMPARATOR
Intervention: Linoleic acid intake of 0% of total energy intake
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Linoleic acid intake of 20% of total energy intake
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Linoleic acid intake (various levels)
Number of subjects: 24
Study: 29445845

Group type: EXPERIMENTAL
Intervention: Written information provided after FC
Number of subjects: 200

Group type: COMPARATOR
Intervention: Verbal information alone (Control)
Number of subjects: 200
Study: 28842084

Group type: EXPERIMENTAL
Intervention: Deep Fascial Approach (DFA)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Superficial Fascial Approach (SFA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: All patients (DFA + SFA)
Number of subjects: 46
Study: 25234807

Group type: EXPERIMENTAL
Intervention: Linezolid therapy (1200 mg per day for 4-6 weeks, then 300-600 mg per day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (standard chemotherapy regimen)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Linezolid therapy
Number of subjects: 65
Study: 23352740

Group type: EXPERIMENTAL
Intervention: Multi-voxel pattern analysis (MVPA) fMRI
Number of subjects: 0
Study: 21982667

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: High-dose clopidogrel 150 mg/day
Number of subjects: 31
Study: 18495027

Group type: EXPERIMENTAL
Intervention: Radio guided occult lesion localization (ROLL)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Wire-guided localization (WGL)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: ROLL
Number of subjects: 316

Group type: COMPARATOR
Intervention: WGL
Number of subjects: 316
Study: 17285968

Group type: EXPERIMENTAL
Intervention: Endonasal sinus surgery with frontal sinus opened and drained by two pipes of silicone for 6 months (Group 1)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Endonasal sinus surgery with frontal sinus opened and drained by two pipes of silicone for 6 months plus injection of beclomethasone (Group 2)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Only frontal sinus opened (Group 3)
Number of subjects: 68
Study: 14603360

Group type: EXPERIMENTAL
Intervention: Personalized photo books as part of a comprehensive nursing intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard brochures as part of a nurse-teaching intervention
Number of subjects: 100
Study: 10970927

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 47

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 47
Study: 8985678

Group type: EXPERIMENTAL
Intervention: Magnetic stimulation applied above the right or left motor cortex at varying time intervals (30 and 110 ms) after a visual stimulus.
Number of subjects: 8

Group type: COMPARATOR
Intervention: No magnetic stimulation (control condition).
Number of subjects: 8
Study: 1457432

Group type: EXPERIMENTAL
Intervention: Warm leukocyte-depleted blood reperfusion (group II; n = 11)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Warm whole blood reperfusion (group I; n = 9)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 6365157

Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 31165160

Group type: EXPERIMENTAL
Intervention: CAM RCTs
Number of subjects: 764
Study: 29635395

Group type: EXPERIMENTAL
Intervention: Accelerated Resolution Therapy (ART); mean number of sessions received: 3.9 ± 1.1.
Number of subjects: 291
Study: 25676540

Group type: EXPERIMENTAL
Intervention: Oral Δ(9)‐THC (maximum 28 mg/day)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Economic evaluation
Number of subjects: 498
Study: 24623718

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study: 21917649

Group type: EXPERIMENTAL
Intervention: Celecoxib treatment for 24 months
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Anti-H pylori treatment for 7 days
Number of subjects: 1024

Group type: COMPARATOR
Intervention: H pylori eradication followed by celecoxib
Number of subjects: 1024
Study: 19687005

Group type: EXPERIMENTAL
Intervention: Telemonitoring with pharmacological treatment for 6 months
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Telemonitoring with pharmacological treatment for 6 months (per-protocol analysis)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Telemonitoring group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Telemonitoring group (hospitalized patients)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 17700083

Group type: EXPERIMENTAL
Intervention: Home-based intervention program (40 visits over 12 months)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (center-based program only)
Number of subjects: 59
Study: 15286098

Group type: EXPERIMENTAL
Intervention: Ximelagatran 36 mg twice daily for 8 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Digoxin 0.5 mg single oral dose on day 4
Number of subjects: 16
Study: 11543692

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 18
Study: 9701198

Group type: EXPERIMENTAL
Intervention: 1.6 mg riboflavin daily for 12 weeks
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 25 mg riboflavin daily for 12 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 8611450

Group type: EXPERIMENTAL
Intervention: Campath‐1H (humanized CD52 monoclonal antibody)
Number of subjects: 9
Study: 2285631

Group type: EXPERIMENTAL
Intervention: Propionyl carnitine (PC) 500 mg three times a day for 30 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PL) three times a day for 30 days
Number of subjects: 18
Study: 6450787

Group type: EXPERIMENTAL
Intervention: Lithium plus placebo
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo plus haloperidol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lithium plus haloperidol
Number of subjects: 21
Study: 31466779

Group type: COMPARATOR
Intervention: Control compensable neutral dry (CN; 23.7 ± 0.7 °C; 10.7 ± 0.8%Rh)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Compensable hot dry (CH; 42.3 ± 0.3 °C; 10.7 ± 1.8%Rh)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Uncompensable hot humid (UCH; 42.3 ± 0.3 °C; 55.2 ± 7.7%Rh)
Number of subjects: 9
Study: 26303352

Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study: 23422378

Group type: EXPERIMENTAL
Intervention: Risperidone or Paliperidone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 21273492

Group type: EXPERIMENTAL
Intervention: GLP-1 administration during meal
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: GLP-1 administration during OGTT
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: GLP-1 administration during hyperglycemic clamps
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Improved glycemic control after 2 months
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: GLP-1 administration after improved glycemic control
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control subjects during meal
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control subjects during OGTT
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Diabetic patients during OGTT
Number of subjects: 28
Study: 20112480

Group type: EXPERIMENTAL
Intervention: Acupuncture plus music therapy (Group Acup. + M)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple acupuncture (Group Acup.)
Number of subjects: 60
Study: 16636212

Group type: EXPERIMENTAL
Intervention: Calcium carbonate, 600 mg twice per day
Number of subjects: 1460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1460
Study: 15388304

Group type: EXPERIMENTAL
Intervention: Attention manipulation by blurring faces and occluding features (Experiment 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Unlimited time presentation of face pairs (Experiment 2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Manipulation of spacing beyond normal limits (Experiment 3)
Number of subjects: 100
Study: 11591548

Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide, 30 mg
Number of subjects: 710

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study: 9334894

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg for > or = 7 weeks
Number of subjects: 8
Study: 8228350

Group type: EXPERIMENTAL
Intervention: Single-dose live oral cholera vaccine strain CVD 103-HgR (5 x 10(9) cfu)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Single-dose live oral cholera vaccine strain CVD 103-HgR
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177

Group type: COMPARATOR
Intervention: Moore swabs in sewers and latrines near households
Number of subjects: 177
Study: 31682582

Group type: EXPERIMENTAL
Intervention: Calm Meditation App usage (average 11.49 months, SD 10.49)
Number of subjects: 12151

Group type: EXPERIMENTAL
Intervention: Calm Meditation App usage duration
Number of subjects: 12151

Group type: EXPERIMENTAL
Intervention: Calm Meditation App usage frequency
Number of subjects: 12151

Group type: EXPERIMENTAL
Intervention: Sleep Stories usage
Number of subjects: 12151
Study: 29426443

Group type: EXPERIMENTAL
Intervention: Cataract surgery (phacoemulsification)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (unoperated fellow eyes)
Number of subjects: 101
Study: 27849497

Group type: EXPERIMENTAL
Intervention: Lumbar extensor high‐intensity progressive resistance exercise (HIPRE) training (n = 298)
Number of subjects: 582

Group type: COMPARATOR
Intervention: Core stabilization exercise training (control) (n = 284)
Number of subjects: 582
Study: 24803481

Group type: EXPERIMENTAL
Intervention: Short lifestyle questionnaire (7 pages)
Number of subjects: 31751

Group type: EXPERIMENTAL
Intervention: Long lifestyle and quality of life questionnaire (10 pages)
Number of subjects: 31751

Group type: COMPARATOR
Intervention: No questionnaire sent
Number of subjects: 31751

Group type: EXPERIMENTAL
Intervention: Overall attendance for those born in 1951
Number of subjects: 31751
Study: 22925356

Group type: EXPERIMENTAL
Intervention: Parent-focused early childhood obesity prevention intervention
Number of subjects: 542

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 542
Study: 20739728

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) added to usual care
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 41
Study: 19089259

Group type: EXPERIMENTAL
Intervention: Manual toothbrush with tongue scraper
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional tongue scraper
Number of subjects: 30
Study: 15957680

Group type: EXPERIMENTAL
Intervention: Experimental intervention
Number of subjects: 232

Group type: COMPARATOR
Intervention: Minimal intervention control
Number of subjects: 232
Study: 11837827

Group type: EXPERIMENTAL
Intervention: Pertrochanteric external fixator (PF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sliding hip screw (SHS)
Number of subjects: 100
Study: 10421260

Group type: EXPERIMENTAL
Intervention: Postoperative intrahepatic arterial chemotherapy (2-3 courses with a maximum dose of 80 mg of cisplatin and 10 mg of mitomycin C at 1-month intervals)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Moderate hepatitis (HAI score of 6-9)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Mild hepatitis (HAI score of 0-5)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Severe hepatitis (HAI score > or = 10)
Number of subjects: 158
Study: 7570405

Group type: EXPERIMENTAL
Intervention: Low dose inhaled steroid (400 micrograms beclomethasone dipropionate) + salmeterol (100 micrograms)
Number of subjects: 426

Group type: COMPARATOR
Intervention: High dose inhaled steroid (1000 micrograms beclomethasone dipropionate)
Number of subjects: 426
Study: 1663774

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 62
Study: 6182894

Group type: EXPERIMENTAL
Intervention: Lidocaine (trimecain) administered intravenously and then intramuscularly for a day
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control group (155 patients)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Lidocaine administered intramuscularly for 1.8 years
Number of subjects: 316
Study: 31821429

Group type: EXPERIMENTAL
Intervention: Fresh red blood cells (stored ≤7 days)
Number of subjects: 1538

Group type: COMPARATOR
Intervention: Standard-issue red blood cells
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: Fresh red blood cells
Number of subjects: 1538
Study: 28206682

Group type: EXPERIMENTAL
Intervention: Low-cost mesh
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial mesh
Number of subjects: 0
Study: 25695849

Group type: EXPERIMENTAL
Intervention: Yoga/meditation (YM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 0
Study: 23392332

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg i.v. (dexamethasone group, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control group, n = 20)
Number of subjects: 40
Study: 21540324

Group type: EXPERIMENTAL
Intervention: Symptomatic benign prostatic hyperplasia (BPH)
Number of subjects: 5068

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5068
Study: 19927630

Group type: EXPERIMENTAL
Intervention: Amiodarone plus irbesartan (150 mg/d)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Amiodarone alone
Number of subjects: 63
Study: 17530099

Group type: EXPERIMENTAL
Intervention: Standard dose E2/NETA (2 mg E2/1 mg NETA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low dose E2/NETA (1 mg E2/0.5 mg NETA)
Number of subjects: 90
Study: 15167457

Group type: EXPERIMENTAL
Intervention: 20 mg lisinopril (LIS) daily for 4 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide (HCT) daily for 4 weeks
Number of subjects: 52
Study: 11483905

Group type: EXPERIMENTAL
Intervention: 20 mg cisapride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9712219

Group type: EXPERIMENTAL
Intervention: Remote interview via telecommunication
Number of subjects: 30

Group type: COMPARATOR
Intervention: In-person interview
Number of subjects: 30
Study: 8067837

Group type: EXPERIMENTAL
Intervention: Low systemic heparinization
Number of subjects: 104

Group type: COMPARATOR
Intervention: Full systemic heparinization
Number of subjects: 104
Study: 2844356

Group type: EXPERIMENTAL
Intervention: Support from care attendants on first day at home for up to 12 hours a week for two weeks
Number of subjects: 903

Group type: COMPARATOR
Intervention: Standard aftercare
Number of subjects: 903
Study: 31952625

Group type: EXPERIMENTAL
Intervention: Supervision with Motivational Enhancing Intervention (MEI)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Supervision as Usual (SAU)
Number of subjects: 220
Study: 31397488

Group type: EXPERIMENTAL
Intervention: telbivudine 600 mg/d oral
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (no antiviral drugs)
Number of subjects: 141
Study: 28193242

Group type: EXPERIMENTAL
Intervention: Pressure ulcer prevention care bundle
Number of subjects: 799
Study: 26216500

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (40-60 mg/day)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Intramuscular adrenocorticotropic hormone (40-60 IU/every other day)
Number of subjects: 97
Study: 23137389

Group type: EXPERIMENTAL
Intervention: Oral altrenogest (0.044 mg/kg; Regumate(®) ) for 11 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intravaginal progesterone (1.38 g; CIDR(®) ) for 11 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intravaginal progesterone (CIDR(®) ) for 8 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 41
Study: 21192268

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 18975103

Group type: EXPERIMENTAL
Intervention: Galantamine (16 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 16427318

Group type: EXPERIMENTAL
Intervention: ARCES (Attention-related Cognitive Errors Scale)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MAAS (Mindful Attention Awareness Scale)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SART (Sustained Attention to Response Task)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BPS (Boredom Proneness Scale)
Number of subjects: 0
Study: 12544071

Group type: EXPERIMENTAL
Intervention: 0.05 mmol/kg Gd‐BOPTA
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0.1 mmol/kg Gd‐DTPA
Number of subjects: 41
Study: 11032589

Group type: EXPERIMENTAL
Intervention: Toremifene 40 mg/d
Number of subjects: 899

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/d
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Toremifene 40 mg/d (ER-positive subgroup)
Number of subjects: 899

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/d (ER-positive subgroup)
Number of subjects: 899
Study: 8955551

Group type: EXPERIMENTAL
Intervention: Short-forms of WAIS-R
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Six- and seven-subtest short-forms
Number of subjects: 624
Study: 1740538

Group type: COMPARATOR
Intervention: HCTZ/TRI (25 mg/50 mg)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Atenolol 25 mg (Ate-25)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Atenolol 50 mg (Ate-50)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg + HCTZ/TRI (Ate-25/HCTZ/TRI)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg + HCTZ/TRI (Ate-50/HCTZ/TRI)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg (Ate-25), Atenolol 50 mg (Ate-50), HCTZ/TRI, Ate-25/HCTZ/TRI, Ate-50/HCTZ/TRI
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: HCTZ/TRI (25 mg/50 mg), Ate-25/HCTZ/TRI, Ate-50/HCTZ/TRI
Number of subjects: 256
Study: 6747020

Group type: EXPERIMENTAL
Intervention: wax‐matrix KCl
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: microencapsulated KCl
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: liquid KCl
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: experimental extended‐release capsules
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: experimental extended‐release tablets
Number of subjects: 90

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study: 31033228

Group type: EXPERIMENTAL
Intervention: Low-load resistance training (30% 1RM) with partial blood-flow restriction training (BFRT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High-load resistance training (HL-RT; 70% 1 repetition maximum [1RM])
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 31022213

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU once daily for four weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (saline once daily for four weeks)
Number of subjects: 16
Study: 27739334

Group type: EXPERIMENTAL
Intervention: Self-referral to inpatient treatment (SRIT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 54
Study: 25214387

Group type: EXPERIMENTAL
Intervention: Multiple-set (MS) resistance training
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Tri-set (TS) resistance training
Number of subjects: 11